We read with interest the study published by Braaten and colleagues, analysing the long-term outcomes of 60 patients developing persistent inflammatory arthritis (IA) after immune checkpoint inhibitors (ICIs) cessation. The most relevant result of the study was the presence of active arthritis in more than half of the patients at the last follow-up visit.1 We report here our experience in the context of a joint oncology/rheumatology outpatient clinic, in order to evaluate the risk of developing IA in patients treated by anti-PD1 drugs. During 1-year period, we consecutively assessed all the adult patients candidate to anti-PD1 treatment, referring to the Oncology Unit at the Sapienza University of Rome. After treatment starts, in the case of musculoskeletal manifestations, patients were referred to the Sapienza Arthritis Center, Rheumatology Unit, Sapienza University of Rome. Arthritis was defined as the occurrence of at least one episode of clinical synovitis, with morning stiffness lasting at least 30 min. …

中文翻译：

---

Braaten 等人关于“免疫检查点抑制剂诱导的炎症性关节炎在免疫治疗停止后持续存在”的对应关系

我们感兴趣地阅读了 Braaten 及其同事发表的研究，该研究分析了 60 名在免疫检查点抑制剂 (ICI) 停用后发展为持续性炎症性关节炎 (IA) 的患者的长期结果。该研究最相关的结果是在最后一次随访中超过一半的患者存在活动性关节炎。1 我们在此报告我们在联合肿瘤/风湿病门诊的经验，以评估接受抗 PD1 药物治疗的患者发生 IA 的风险。在 1 年期间，我们连续评估了所有候选抗 PD1 治疗的成年患者，参考了罗马第一大学的肿瘤科。治疗开始后，如果出现肌肉骨骼表现，患者被转诊至 Sapienza 关节炎中心风湿病科，罗马第一大学。关节炎被定义为发生至少一次临床滑膜炎，晨僵持续至少 30 分钟。…